Sharma V, Riddle A, Mason B, Whitehead M, Collins W
Hallam Medical Centre, London, United Kingdom.
Fertil Steril. 1989 Feb;51(2):298-303. doi: 10.1016/s0015-0282(16)60494-6.
The authors have undertaken a prospective, randomized clinical trial of six treatments to optimize folliculogenesis in patients prior to oocyte collection, in vitro fertilization, and embryo transfer. All treatments involved the administration of the same daily dose of follicle-stimulating hormone (FSH), but at different times during the antecedent and/or current menstrual cycle. There was a significant difference (P less than 0.01, chi-square test) between treatments in the clinical pregnancy rate/patient (19 clinical pregnancies, 67 patients). No advantages were observed for regimens that involved starting treatment during the antecedent cycle. The study was continued with the three treatments that started during the current cycle (24 clinical pregnancies, 58 patients). The most cost-effective regimen was clomiphene citrate, 100 mg/day for days 2 to 6 inclusive; FSH, 150 units/day for days 1 to 4 inclusive; and human menopausal gonadotropin, 150 units/day from day 5 until the day of human chorionic gonadotropin administration.
作者进行了一项前瞻性随机临床试验，对六种治疗方法进行研究，以优化卵母细胞采集、体外受精和胚胎移植前患者的卵泡生成。所有治疗均涉及每日给予相同剂量的促卵泡激素（FSH），但在前期和/或当前月经周期的不同时间给药。各治疗组间临床妊娠率/患者存在显著差异（P<0.01，卡方检验）（19例临床妊娠，67例患者）。未观察到在前一周期开始治疗的方案有任何优势。研究继续对在当前周期开始的三种治疗方法进行（24例临床妊娠，58例患者）。最具成本效益的方案是：枸橼酸氯米芬，第2至6天（含第2天和第6天）每日100毫克；FSH，第1至4天（含第1天和第4天）每日150单位；人绝经期促性腺激素，从第5天至注射人绒毛膜促性腺激素当天每日150单位。
